Pharma Marketing News
News & Views for
Responsible Marketers

Messages from Our Sponsors

Pharma Glossary

Pharmaguy's Picks

Pharma Marketing Network Curated Content Forums
The Leading Online Source of Curated Content for Pharmaceutical Marketing Experts
Newsletter | Conferences | Podcasts | Glossary | Surveys | Blog | Advertising Information | Contact Us

"Must Read Blog for Insiders." -- Wall Street Journal
Pharma Marketing News
Current Issue of Pharma Marketing News Available!

Search the Entire Pharma Marketing Forums Site

Go Back   Pharma Marketing Network Curated Content > Pharmaceutical Marketing & Communications > Internet and Social Media Marketing

Internet and Social Media Marketing Topics & news related to pharma marketing via the Internet in general and social media in particular.

Thread Tools Rate Thread Display Modes
Old 3rd June 2011, 05:49 AM
Pharma Newshound Pharma Newshound is offline
News Gatherer
Join Date: Dec 2007
Location: USA
Posts: 11,017
Default New Facebook Policy "Kind of Hurts" Pharma Marketers

Source: Advertising Age

New Facebook Policy Spurs Big Pharma to Rethink Social Media Strategy
Major Marketers Fear that Enabling Comments Will Attract FDA Ire

*** Listen to this Pharma Marketing Talk podcast: "Pharma Facebook Commenting Changes: The Final Story" with guest Jonathan Richman ***

Pharmaceutical marketers are stuck between a rock and a hard place when it comes to social media -- they are trying hard to embrace it, but the very nature of the two-way dialogue endemic to the medium threatens to work against them. Case in point: Facebook's new policy that will no longer allow drug makers to disable the comments feature on their pages.

Being forced to enable comments on its Facebook pages puts pharmaceutical companies at risk of running afoul of the current Food and Drug Administration regulations, even if it's only consumers making the comments. For instance, if a company has a branded page for an antacid, and a consumer comments that it helped lower his blood pressure as well, that's considered off-label promotion and the FDA could conceivably send a warning letter to the company. Some companies are concerned even though Facebook said it will consider allowing the comment function to be removed for branded drug pages, where it is more likely those kinds of comments will turn up.

"This kind of hurts us," said a digital-strategy chief at one of the top 10 pharma companies regarding the new policy, which takes effect Aug. 15. "In large part, having a Facebook page gets us in the social media door and not having comments keeps us in good graces with FDA. "

"We're standing on the sideline of a nice fight between two 800-pound gorillas," said Jim Dayton, senior director of emerging media for Overland Park, Kan.-based InTouch Solutions, a pharma-centric digital-marketing agency. Mr. Dayton and InTouch received a copy of the letter Facebook sent to pharma companies, and posted the missive on its site.

"I'm reaching out to inform you of a policy change regarding pharma pages on Facebook that may affect one or more of your brand pages," it reads. "As you know, Facebook pages are a free product for organizations, public figures, businesses and brands to express themselves and have an authentic, engaging, two-way dialogue with people on Facebook. Previously, pharmaceutical brands could submit a request through their Facebook sales representative to disable commenting on their Facebook page. Starting today, Facebook will no longer allow admins of new pharma pages to disable commenting on the content their page shares with people on Facebook. ... Subject to Facebook's approval, branded pages solely dedicated to a prescription drug may [continue to] have commenting functionality removed."

The letter continues: "We think these policy changes support consistency for the Facebook Pages product and encourage an authentic dialogue between people and businesses on Facebook. However, we also understand that these changes may lead you to re-evaluate your strategy and presence on Facebook. We are committed to helping you during this transition."

Former FDA associate commissioner Peter Pitts, now the president of the Center for Medicine in the Public Interest, said the FDA has made it clear that it is not going to issue platform-specific guidance on social media, so drug makers shouldn't sit around and wait.

"The Facebook decision is entirely consistent with what Facebook is designed to be -- interactive. A Facebook page with the interactivity turned off is just a static web page residing on an interactive platform. And that isn't what Facebook is all about," Mr. Pitts said. "It's time for regulated industry to step up to the plate and embrace the powerful tool that is real-time interactivity."

Jonathan Richman, group director-insights and planning for Cincinnati-based agency Possible Worldwide, said some pharma companies already have comments enabled on their Facebook pages and it has yet to result in an FDA warning letter. "How much risk do the comments others leave on your posts incur? I'd argue that they produce very little risk," he said. "If someone posts something inappropriate, you still have the ability to delete it. But there will be some panic about this among pharma companies. Some will take down their pages completely."

And some with good reason, according to the digital-strategy chief, who said the industry is concerned that comments could include attacks on the company and outright misinformation. "Unless we can come to some sort of agreement with Facebook on the whole comments thing, it basically comes down to every pharma [company] having to decide whether Facebook is going to be part of their marketing. I don't see a gray area."

A Facebook spokeswoman said that the company does not comment on conversations with clients. But its official statement indicates some wiggle room. "In an effort to encourage conversations between brands and people, we recently made some changes to our policies that affect some official pharmaceutical pages directed at building communities. This change does not affect pages for prescription drugs. We think these changes will help encourage an authentic dialogue on pages."

And with social media expanding every day and Facebook offering access to half a billion people, it's a gamble drug makers might have to take. "I don't think pharma will abandon Facebook," said Mike Guarini, president of ad agency Ryan True Health, Wilton, Conn., and a former pharmaceutical-company ad exec with Bristol-Myers Squibb. "I think pharma will proceed more deliberately with social media, but they won't abandon it."
Pharma Newshound
"I sift through the news so you don't have to!"

Please take the PMN Forums Visitor Survey and help us provide a better experience. It will only take 1 minute of your time.

Got news? Tell me about it:
Reply With Quote
Old 22nd June 2011, 07:39 PM
RonaldR RonaldR is offline
Join Date: Jun 2011
Location: USA
Posts: 2

There are now several business that start using the advantage of Facebook to help you with promoting your sales and products online.
Facebook webinars
Reply With Quote
Old 13th July 2011, 02:45 AM
david1steven's Avatar
david1steven david1steven is offline
Join Date: Jul 2011
Location: USA
Posts: 1
Send a message via Yahoo to david1steven

Facebook is the today's best social networking site and it helps to promote your business. So it is said that facebook is best for marketing.
social media monitoring
Reply With Quote

Thread Tools
Display Modes Rate This Thread
Rate This Thread:

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is On
Forum Jump

All times are GMT -5. The time now is 07:14 PM.

Powered by vBulletin® Version 3.6.4
Copyright ©2000 - 2014, Jelsoft Enterprises Ltd.
(c) 2014, Pharma Marketing Network. All rights reserved.